Tissue plasminogen activator and patients with acute ischemic stroke: The litigation landscape
Abstract Objective Tissue plasminogen activator (tPA) is considered standard of care for acute ischemic stroke treatment, but some physicians withhold or delay this highly time‐dependent therapy from stroke patients because they do not think it works well or they are worried about the adverse effect...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-02-01
|
| Series: | Journal of the American College of Emergency Physicians Open |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/emp2.12646 |